These findings suggest that concurrent therapies with EDTA and MUC7 12-mer may be of value in patients with oral fungal or bacterial infections, although further studies in vivo are needed to examine the safety, tolerance, and optimal dosing of EDTA in the treatment of these infections. Here, MUC7 is linked to infection.